• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Quality

    Alembic Pharmaceuticals gets US FDA EIR for Panelav Oncology Site

    EXPRESSPHARMA

    Alembic Pharma`s Vadodara Facility Gets One USFDA 483

    BUSINESS STD

    Alembic Pharma Gujarat facility gets 5 observations from USFDA

    BUSINESS STD

    Alembic rises after oncology completes FDA with `zero` observations

    BUSINESS STD

    Alembic Pharmaceuticals receives EIR from USFDA for oncoformulation facility

    INDINPHARMAPOST

    USFDA conducts inspection at Alembic Pharmaceuticals` Panelav oncology formulation facility

    INDIANPHARMAPOST

    Alembic, Aurobindo Pharma issue separate US drug recalls

    FIERCE PHARMA

    Alembic Pharma gets EIR from USFDA for its solid oral formulation facility

    EXPRESS PHARMA

    Alembic Pharmaceuticals receives 2 observations for Gujarat facility from USFDA

    ECONOMIC TIMES

    USFDA Inspection, Alembic Pharma Gets Form 483 with 5 observations

    MEDICAL DIALOGUES

    Alembic Pharma slips as US FDA issues Form 483 to Panelav facility

    BUSINESS-STANDARD

    Alembic Pharma receives 4 observations from USFDA for Panelav facility

    ECONOMIC TIMES

    Alembic gets USFDA nod for Vilazodone Hcl tablets to treat depression

    ECONOMICTIMES

    Alembic Pharma announces successful completion of USFDA inspection

    INDIA INFOLINE

    Alembic Pharmaceuticals rises 3% on EIR for Karakhadi unit from USFDA

    MONEYCONTROL

    Alembic Pharma gains on receiving EIR for Panelav formulation facility

    MONEYCONTROL

    Valsartan products not currently recalled - Updated November 27, 2018

    FDA

    Valsartan products not currently recalled - Updated August 8, 2018

    FDA

    Alembic receives FDA 483, but no repeat observations nor data issues

    IN PHARMATECHNOLOGIST

    Awesome Baby; We Love This Game! An Update on Pending Hatch-Waxman and BPCIA Litigation

    FDA LAW BLOG

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.